Clinical Trials Logo

Clinical Trial Summary

M-Trap is an implantable medical device designed to capture disseminated tumor cells (DTCs). It is intended for use in advanced-stage ovarian cancer patients. The study objective is to assess the safety and the performance of the M-Trap device.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03085238
Study type Interventional
Source MTrap, Inc.
Contact
Status Completed
Phase N/A
Start date March 9, 2017
Completion date December 31, 2019

See also
  Status Clinical Trial Phase
Completed NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer Phase 1
Completed NCT00945191 - Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer Phase 2
Recruiting NCT03579394 - Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer N/A
Recruiting NCT04701645 - Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer Phase 1
Completed NCT03126812 - Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer Phase 1/Phase 2
Terminated NCT03162562 - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Phase 1
Active, not recruiting NCT03922776 - Phenotypic Characterization Tumor-infiltrating Lymphocytes at Diagnosis and After Chemotherapy in Ovarian Cancer N/A
Recruiting NCT04938583 - Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Phase 1/Phase 2
Not yet recruiting NCT06017557 - Predicting Outcome of Cytoreduction in Advanced Ovarian Cancer, Using a Machine Learning Algorithm and Patterns of Disease Distribution at Laparoscopy (PREDAtOOR) N/A
Suspended NCT05479045 - A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients Phase 2
Completed NCT05005650 - Survival Impact of Internal Mammary or Supraclavicular Lymphadenectomy
Recruiting NCT03899610 - A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D) Phase 2
Recruiting NCT04789694 - Prehabilitation in Gynaecological Cancer Patients Phase 3
Not yet recruiting NCT05187208 - PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer Phase 4
Recruiting NCT06272240 - Tumor Microenvironment in Ovarian Cancer
Not yet recruiting NCT06268665 - Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy Phase 2
Active, not recruiting NCT03275506 - PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer . Phase 2
Recruiting NCT06290193 - Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Primary Cytoreductive Surgery Phase 2
Completed NCT02258165 - Impact of Gated PET/CT in the Diagnosis of Advanced Ovarian Cancer
Recruiting NCT03693248 - Reduction Of Cycles of neOadjuvant Chemotherapy for Advanced Epithelial Ovarian, Fallopian and Primary Peritoneal Cancer Phase 3